Puig-Domingo Manel, Díaz Gonzalo, Nicolau Joanna, Fernández Cristián, Rueda Sergio, Halperin Irene
Servei de Endocrinologia, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.
Eur J Endocrinol. 2008 Nov;159(5):653-7. doi: 10.1530/EJE-08-0269. Epub 2008 Aug 14.
Hypoparathyroidism is usually controlled with calcium and vitamin-D supplements; in very few cases this treatment fails and teriparatide may be an alternative. We report the first case of hypoparathyroidism refractory to vitamin-D therapy requiring multipulse teriparatide treatment.
A 53 year-old woman presented severe hypocalcemia and hypomagnesemia after thyroidectomy. Preoperatively, mild hypercalciuria was detected with parathyroid hormone (PTH) 69 pg/ml (normal 10-45) and 25-OH-vitamin D 9 ng/ml (normal 20-40) and normal levels of magnesium. No response was seen with oral and i.v. calcium and magnesium, or even with 5 microg calcitriol/day, suggesting a vitamin-D resistance status. Calcium sensor and vitamin-D receptor gene mutation studies were negative.
The following treatments were tried: i) s.c. recombinant human PTH (rhPTH) 1-34 plus oral calcitriol, calcium, and magnesium, was partially effective, but symptoms resumed 4 h after the injection of 20 microg rhPTH; stable calcemia was not achieved even with 4-6 injections/day of teriparatide; ii) two trials of heterologous parathyroid transplant were performed but rejection was detected 3 months after; iii) i.v. magnesium decreased rhPTH requirements but i.m. administration was not tolerated and iv) multipulse s.c. infusion of teriparatide achieved complete normalization of serum calcium, phosphate, magnesium, calciuria and magnesuria with relatively low rhPTH doses (25-35 microg/day) for more than a year.
Vitamin-D unresponsiveness leads to uncontrolled hypocalcemia when postsurgical hypoparathyroidism occurs; in situations of no response to usual or higher doses of vitamin-D and s.c. injections of rhPTH, treatment with teriparatide multipulse s.c. infusor is an effective and safe alternative.
甲状旁腺功能减退症通常通过补充钙和维生素 D 来控制;在极少数情况下,这种治疗会失败,而特立帕肽可能是一种替代方案。我们报告了第一例对维生素 D 治疗难治的甲状旁腺功能减退症病例,该病例需要多次注射特立帕肽治疗。
一名 53 岁女性在甲状腺切除术后出现严重低钙血症和低镁血症。术前,检测到轻度高钙尿症,甲状旁腺激素(PTH)为 69 pg/ml(正常范围 10 - 45),25 - 羟基维生素 D 为 9 ng/ml(正常范围 20 - 40),镁水平正常。口服和静脉注射钙和镁,甚至每日 5 微克骨化三醇治疗均无反应,提示存在维生素 D 抵抗状态。钙敏感受体和维生素 D 受体基因突变研究结果为阴性。
尝试了以下治疗方法:i)皮下注射重组人 PTH(rhPTH)1 - 34 联合口服骨化三醇、钙和镁,部分有效,但注射 20 微克 rhPTH 后 4 小时症状复发;即使每天注射 4 - 6 次特立帕肽,也未实现血钙稳定;ii)进行了两次异体甲状旁腺移植试验,但 3 个月后检测到排斥反应;iii)静脉注射镁可降低 rhPTH 需求量,但肌肉注射无法耐受;iv)多次皮下输注特立帕肽,以相对较低的 rhPTH 剂量(每日 25 - 35 微克)使血清钙、磷、镁、尿钙和尿镁完全恢复正常,且持续了一年多。
术后甲状旁腺功能减退症发生时,维生素 D 无反应会导致低钙血症无法控制;在对常规剂量或更高剂量维生素 D 及皮下注射 rhPTH 无反应的情况下,使用特立帕肽多次皮下输注器治疗是一种有效且安全的替代方法。